A combination of circulating tumor cells and CA199 improves the diagnosis of pancreatic cancer

Early diagnosis of pancreatic ductal adenocarcinoma (PDAC) is difficult due to the lack of effective screening tests. CA199, the standard biomarker for PDAC management, is not sufficiently reliable for early diagnosis. This prospective study aimed to evaluate whether circulating tumor cells (CTCs) could complement or perform better than CA199 in determining PDAC.

[1]  T. Lawrence,et al.  Expansion of Circulating Tumor Cells from Patients with Locally Advanced Pancreatic Cancer Enable Patient Derived Xenografts and Functional Studies for Personalized Medicine , 2020, Cancers.

[2]  Shelly C. Lu,et al.  Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma , 2020, Hepatology.

[3]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[4]  V. Bobek,et al.  Circulating tumor cells in gynaecological malignancies. , 2020, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[5]  Michaela Patterson,et al.  Residual diploidy in polyploid tissues: a cellular state with enhanced proliferative capacity for tissue regeneration? , 2019, Stem cells and development.

[6]  S. Fichtner-Feigl,et al.  Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives , 2019, Cancers.

[7]  C. L. Chaffer,et al.  The Complexities of Metastasis , 2019, Cancers.

[8]  E. Rossi,et al.  CTCs 2020: Great Expectations or Unreasonable Dreams , 2019, Cells.

[9]  Lynette M. Smith,et al.  Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer , 2019, EBioMedicine.

[10]  Y. Liu,et al.  The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis , 2019, Clinical Cancer Research.

[11]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[12]  Guojun Ma,et al.  Improvement of sensitive and specific detection of circulating tumor cells using negative enrichment and immunostaining-FISH. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[13]  A. Vanoli,et al.  c-MYC amplification and c-myc protein expression in pancreatic acinar cell carcinomas. New insights into the molecular signature of these rare cancers , 2018, Virchows Archiv.

[14]  Sabine Riethdorf,et al.  Clinical applications of the CellSearch platform in cancer patients. , 2018, Advanced drug delivery reviews.

[15]  T. Pawlik,et al.  8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers , 2018, Annals of Surgical Oncology.

[16]  T. Graeber,et al.  Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer , 2018, Annals of Surgical Oncology.

[17]  M. Pitman,et al.  Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations , 2017, Scientific Reports.

[18]  Han Liu,et al.  Circulating Tumor Cells as a Biomarker in Pancreatic Ductal Adenocarcinoma , 2017, Cellular Physiology and Biochemistry.

[19]  B. Jenkins,et al.  Endoscopic ultrasound‐guided fine‐needle aspirate‐derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild‐type tumors , 2017, International journal of cancer.

[20]  A. Wu,et al.  Current detection technologies for circulating tumor cells. , 2017, Chemical Society reviews.

[21]  S. Natsugoe,et al.  Clinical impact of circulating tumor cells and therapy response in pancreatic cancer. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[22]  Lynette M. Smith,et al.  A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study , 2017, The American Journal of Gastroenterology.

[23]  J. Cameron,et al.  Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma , 2016, Annals of surgery.

[24]  T. Graeber,et al.  Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer , 2016, British Journal of Cancer.

[25]  M. Al-Hawary.  Role of Imaging in Diagnosing and Staging Pancreatic Cancer. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[26]  Xinyu Huang,et al.  Clinical significance of pancreatic circulating tumor cells using combined negative enrichment and immunostaining-fluorescence in situ hybridization , 2016, Journal of Experimental & Clinical Cancer Research.

[27]  M R Speicher,et al.  The biology of circulating tumor cells , 2016, Oncogene.

[28]  N. Malats,et al.  Circulating tumor cells (CTC) and KRAS mutant circulating free DNA (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer , 2015, BMC Cancer.

[29]  J. Sadowska,et al.  Endothelium and cancer metastasis: Perspectives for antimetastatic therapy , 2015, Pharmacological reports : PR.

[30]  K. Lillemoe,et al.  Circulating Tumor Cells Found in Patients With Localized and Advanced Pancreatic Cancer , 2015, Pancreas.

[31]  M. Braga,et al.  Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer , 2015, Tumor Biology.

[32]  M. Kloor,et al.  Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases , 2014, Virchows Archiv.

[33]  E. Diamandis,et al.  Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer , 2014, Clinical Cancer Research.

[34]  Ye Guo,et al.  Improvement of specific detection of circulating tumor cells using combined CD45 staining and fluorescence in situ hybridization. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[35]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[36]  F. Bidard,et al.  Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Andrew J Ewald,et al.  ECM microenvironment regulates collective migration and local dissemination in normal and malignant mammary epithelium , 2012, Proceedings of the National Academy of Sciences.

[38]  T. Itoi,et al.  Tumor seeding after endoscopic ultrasound-guided fine-needle aspiration of cancer in the body of the pancreas , 2012, Endoscopy.

[39]  David Pellman,et al.  Causes and consequences of aneuploidy in cancer , 2012, Nature Reviews Genetics.

[40]  Maximilian Reichert,et al.  EMT and Dissemination Precede Pancreatic Tumor Formation , 2012, Cell.

[41]  L Khoja,et al.  A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker , 2011, British Journal of Cancer.

[42]  F. Itokawa,et al.  Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. , 2008, Journal of hepato-biliary-pancreatic surgery.

[43]  Wolfgang Schima,et al.  Pancreatic adenocarcinoma , 2006, European Radiology.

[44]  Geert J. P. L. Kops,et al.  On the road to cancer: aneuploidy and the mitotic checkpoint , 2005, Nature Reviews Cancer.

[45]  H. Kalthoff,et al.  Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival , 2005, Journal of Cancer Research and Clinical Oncology.

[46]  Tanja Fehm,et al.  Circulating Tumor Cells in Patients with Breast Cancer Dormancy , 2004, Clinical Cancer Research.